Skip to content

Apixaban for Extended venous thromboembolism after total hip arthroplasty for femoral neck fracture: a prospective, randomised controlled trial

Apixaban for Extended venous thromboembolism after total hip arthroplasty for femoral neck fracture: a prospective, randomised controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051189
Enrollment
Unknown
Registered
2021-09-15
Start date
2021-09-15
Completion date
Unknown
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

femoral neck fracture

Interventions

Group A:Take Apixaban for 7 weeks
Group B:Take Apixaban for 2 weeks

Sponsors

Dujiangyan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Hospitalized in the Department of Orthopedics of Dujiangyan Medical Center for surgical treatment due to hip fracture; 2. Aged 50-80 years; 3. Body mass index is 20-35 kg/m2; 4. The preoperative American Society of Anesthesiologists (ASA) classification (anesthesia risk assessment) is grade I-III; 5. The patients and their family members gave informed consent and signed the informed consent form, with good compliance and willingness to cooperate with follow-up visits.

Exclusion criteria

Exclusion criteria: 1. The platelet count is less than 100 x 10^9/L; 2. Hemoglobin is less than 100g/L; 3. The daily dose of aspirin is greater than 100 mg; 4. Creatinine clearance rate is less than 30ml/min; 5. Blood AST and ALT are 2 times higher than the upper limit of normal or total bilirubin is higher than 1.5 times the upper limit of normal; 6. History of major brain, spine and ophthalmic surgery or trauma within the past 90 days; 7. The patient is allergic to the test drug; 8. The investigator believes that the patient has other conditions that are not suitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
Incidence of VTE;

Secondary

MeasureTime frame
Major bleeding;Incidence of Adverse Event;

Countries

China

Contacts

Public ContactYin Bao

Dujiangyan People's Hospital

yinbaogk@126.com+86 17780621726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026